Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screening

2 Feb 2023

Abstract excerpt

Abstract There is currently a lack of efficacious treatments for patients with chemo-resistant small-cell lung cancer (SCLC), leading to poor prognoses. We examined a chemo-resistant SCLC cell line using genome-wide CRISPR/Cas9 screening and identified serine/threonine kinase cell division cycle 7 (CDC7) as a potential synergistic target. Silencing CDC7 in chemo-resistant SCLC cells decreased the IC50 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced biosensing and bioanalysis techniques
Share to Cancer Mechanisms and Therapy
Share to CRISPR and Genetic Engineering

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36725843
DOI: 10.1038/s41420-023-01315-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identifying CDC7 as a synergistic target of chemotherapy in resistant small-cell lung cancer via CRISPR/Cas9 screeningPMID 36725843Read ↗

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancerSemantic proximity Read ↗

KDM6B Inhibition Enhances Chemotherapeutic Response in Small Cell Lung Cancer via Epigenetic Regulation of Apoptosis and FerroptosisSemantic proximity Read ↗

Expression of CDCA7 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-small Cell Lung Cancer Semantic proximity Read ↗

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulationSemantic proximity Read ↗

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancerSemantic proximity Read ↗

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.Semantic proximity Read ↗

PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve ResponsesSemantic proximity Read ↗

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with CisplatinSemantic proximity Read ↗

Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT/BCL2/BECN1 pathwaySemantic proximity Read ↗

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recoverySemantic proximity Read ↗

Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.